As of February 2025, ENZOEYS has achieved a major breakthrough in mid-infrared femtosecond laser technology, successfully developing the world's first long-wave infrared continuously tunable tabletop femtosecond laser (LWIRFS). The technical parameters of this laser are impressive: it has a tuning range of 5-11 microns, covering major mid-infrared molecular absorption peaks; the maximum output power exceeds 1 watt, with pulse energy > 2 microjoules, pulse width < 300 femtoseconds, and a repetition rate of 500 kilohertz. Compared with traditional lasers, this product solves the 30-year bottleneck of insufficient power and non-tunability in mid-infrared femtosecond lasers, achieving higher conversion efficiency and lower tissue damage, thus showing great application potential in ultra-precision medical and scientific research fields. Its technical indicators have been evaluated by third-party authoritative institutions such as Sichuan Association for Promotion of Science and Technology Collaborative Innovation and Southwest Information Center of the Ministry of Science and Technology, reaching the international advanced level. Currently, there are no similar benchmark products worldwide.
In the fields of medical aesthetics and skin repair, ENZOEYS' mid-infrared femtosecond laser technology demonstrates unique advantages. A single irradiation can increase collagen by 6%-7%, which is used for anti-aging and skin rejuvenation without side effects such as cavitation; in terms of hair loss treatment, it stimulates the proliferation of hair follicle glands to promote hair regrowth, providing a painless, non-invasive solution for hair loss and addressing the pain points of traditional hair transplantation.
Looking at the global femtosecond laser market, its scale is expected to reach 5.4 billion US dollars by 2026. ENZOEYS plans to obtain Class II and Class III medical device licenses in the next 3-5 years to promote industrialization layout. If clinical trials proceed smoothly, related products are expected to become a new growth driver in the hundred-billion-level medical market. However, the cycle from research and development to market launch of medical products is relatively long, requiring clinical trials and license approval. It is expected that the Class II license will be approved as early as 2025, and the Class III license may be delayed until after 2026, so it is difficult to generate large-scale revenue in the short term. In addition, although Hymson leads in core technical indicators such as power (watt-level), repetition rate (500kHz), and wavelength tuning (5-11μm), the medical laser field is highly competitive. International giants such as Lumenis and Cynosure, as well as domestic emerging enterprises, are accelerating their pursuit. Hymson needs to continue to invest in research and development to maintain its technological leading edge.
